GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » Cyclically Adjusted Revenue per Share

Nxera Pharma Co (Nxera Pharma Co) Cyclically Adjusted Revenue per Share : $1.05 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nxera Pharma Co's adjusted revenue per share for the three months ended in Dec. 2023 was $0.605. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.05 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Nxera Pharma Co's average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Nxera Pharma Co was 15.90% per year. The lowest was 15.40% per year. And the median was 15.70% per year.

As of today (2024-04-30), Nxera Pharma Co's current stock price is $9.3039. Nxera Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.05. Nxera Pharma Co's Cyclically Adjusted PS Ratio of today is 8.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nxera Pharma Co was 42.01. The lowest was 8.60. And the median was 17.67.


Nxera Pharma Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Nxera Pharma Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Cyclically Adjusted Revenue per Share Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 0.85 1.04 0.72 1.05

Nxera Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 1.02 0.97 0.96 1.05

Competitive Comparison of Nxera Pharma Co's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Nxera Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Cyclically Adjusted PS Ratio falls into.



Nxera Pharma Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nxera Pharma Co's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.605/106.8000*106.8000
=0.605

Current CPI (Dec. 2023) = 106.8000.

Nxera Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.045 95.700 0.050
201406 0.042 98.000 0.046
201409 0.055 98.500 0.060
201412 0.058 97.900 0.063
201503 0.406 97.900 0.443
201506 0.084 98.400 0.091
201509 0.288 98.500 0.312
201512 0.646 98.100 0.703
201603 0.054 97.900 0.059
201606 2.111 98.100 2.298
201609 0.109 98.000 0.119
201612 0.155 98.400 0.168
201703 0.244 98.100 0.266
201706 0.370 98.500 0.401
201709 0.336 98.800 0.363
201712 0.126 99.400 0.135
201803 0.080 99.200 0.086
201806 0.100 99.200 0.108
201809 0.113 99.900 0.121
201812 0.125 99.700 0.134
201903 0.369 99.700 0.395
201906 0.232 99.800 0.248
201909 0.324 100.100 0.346
201912 0.229 100.500 0.243
202003 0.134 100.300 0.143
202006 0.163 99.900 0.174
202009 0.222 99.900 0.237
202012 0.565 99.300 0.608
202103 0.138 99.900 0.148
202106 0.215 99.500 0.231
202109 0.052 100.100 0.055
202112 1.424 100.100 1.519
202203 0.116 101.100 0.123
202206 0.122 101.800 0.128
202209 0.522 103.100 0.541
202212 0.603 104.100 0.619
202303 0.086 104.400 0.088
202306 0.104 105.200 0.106
202309 0.273 106.200 0.275
202312 0.605 106.800 0.605

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Nxera Pharma Co  (OTCPK:SOLTF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nxera Pharma Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=9.3039/1.05
=8.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nxera Pharma Co was 42.01. The lowest was 8.60. And the median was 17.67.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nxera Pharma Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co (Nxera Pharma Co) Business Description

Industry
Traded in Other Exchanges
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (Nxera Pharma Co) Headlines

From GuruFocus